全文获取类型
收费全文 | 67823篇 |
免费 | 3704篇 |
国内免费 | 168篇 |
专业分类
耳鼻咽喉 | 871篇 |
儿科学 | 1511篇 |
妇产科学 | 1357篇 |
基础医学 | 8985篇 |
口腔科学 | 2620篇 |
临床医学 | 5200篇 |
内科学 | 16936篇 |
皮肤病学 | 1664篇 |
神经病学 | 5938篇 |
特种医学 | 1726篇 |
外科学 | 9113篇 |
综合类 | 287篇 |
一般理论 | 26篇 |
预防医学 | 5812篇 |
眼科学 | 1264篇 |
药学 | 4474篇 |
中国医学 | 250篇 |
肿瘤学 | 3661篇 |
出版年
2024年 | 47篇 |
2023年 | 453篇 |
2022年 | 205篇 |
2021年 | 1117篇 |
2020年 | 654篇 |
2019年 | 1179篇 |
2018年 | 2078篇 |
2017年 | 1242篇 |
2016年 | 1324篇 |
2015年 | 2028篇 |
2014年 | 2064篇 |
2013年 | 3008篇 |
2012年 | 5890篇 |
2011年 | 5751篇 |
2010年 | 2633篇 |
2009年 | 1946篇 |
2008年 | 4891篇 |
2007年 | 5081篇 |
2006年 | 5261篇 |
2005年 | 4966篇 |
2004年 | 4465篇 |
2003年 | 4016篇 |
2002年 | 3887篇 |
2001年 | 1584篇 |
2000年 | 2086篇 |
1999年 | 1003篇 |
1998年 | 244篇 |
1997年 | 192篇 |
1996年 | 181篇 |
1995年 | 171篇 |
1994年 | 129篇 |
1993年 | 118篇 |
1992年 | 125篇 |
1991年 | 119篇 |
1990年 | 83篇 |
1989年 | 100篇 |
1988年 | 86篇 |
1987年 | 68篇 |
1986年 | 86篇 |
1985年 | 97篇 |
1984年 | 102篇 |
1983年 | 71篇 |
1982年 | 93篇 |
1981年 | 76篇 |
1980年 | 88篇 |
1979年 | 53篇 |
1978年 | 50篇 |
1977年 | 45篇 |
1976年 | 48篇 |
1974年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
Moyé LA 《Progress in cardiovascular diseases》2012,54(4):338-342
Subgroup analysis in a clinical trial is the evaluation of the effect of a randomly allocated intervention within only a fraction of the patients in the entire research cohort. This article provides several examples of the use of subgroup analysis, discusses some of the interpretative difficulties that occur during the assessment of the effect of therapy within subgroups, and provides a summary of recent recommendations on reporting subgroup analyses in the literature. Although subgroup analyses can provide new, provocative, and sometimes clinically relevant findings, this group of evaluations must be handled with extreme care. 相似文献
993.
994.
995.
996.
Tomé-Carneiro J Gonzálvez M Larrosa M Yáñez-Gascón MJ García-Almagro FJ Ruiz-Ros JA García-Conesa MT Tomás-Barberán FA Espín JC 《The American journal of cardiology》2012,110(3):356-363
The search for complementary treatments in primary prevention of cardiovascular disease (CVD) is a high-priority challenge. Grape and wine polyphenol resveratrol confers CV benefits, in part by exerting anti-inflammatory effects. However, the evidence in human long-term clinical trials has yet to be established. We aimed to investigate the effects of a dietary resveratrol-rich grape supplement on the inflammatory and fibrinolytic status of subjects at high risk of CVD and treated according to current guidelines for primary prevention of CVD. Seventy-five patients undergoing primary prevention of CVD participated in this triple-blinded, randomized, parallel, dose-response, placebo-controlled, 1-year follow-up trial. Patients, allocated in 3 groups, consumed placebo (maltodextrin), a resveratrol-rich grape supplement (resveratrol 8 mg), or a conventional grape supplement lacking resveratrol, for the first 6 months and a double dose for the next 6 months. In contrast to placebo and conventional grape supplement, the resveratrol-rich grape supplement significantly decreased high-sensitivity C-reactive protein (-26%, p = 0.03), tumor necrosis factor-α (-19.8%, p = 0.01), plasminogen activator inhibitor type 1 (-16.8%, p = 0.03), and interleukin-6/interleukin-10 ratio (-24%, p = 0.04) and increased anti-inflammatory interleukin-10 (19.8%, p = 0.00). Adiponectin (6.5%, p = 0.07) and soluble intercellular adhesion molecule-1 (-5.7%, p = 0.06) tended to increase and decrease, respectively. No adverse effects were observed in any patient. In conclusion, 1-year consumption of a resveratrol-rich grape supplement improved the inflammatory and fibrinolytic status in patients who were on statins for primary prevention of CVD and at high CVD risk (i.e., with diabetes or hypercholesterolemia plus ≥1 other CV risk factor). Our results show for the first time that a dietary intervention with grape resveratrol could complement the gold standard therapy in the primary prevention of CVD. 相似文献
997.
998.
999.
Manetti M Allanore Y Saad M Fatini C Cohignac V Guiducci S Romano E Airó P Caramaschi P Tinazzi I Riccieri V Della Rossa A Abbate R Caporali R Cuomo G Valesini G Dieudé P Hachulla E Cracowski JL Tiev K Letenneur L Amouyel P Lambert JC Chiocchia G Martinez M Ibba-Manneschi L Matucci-Cerinic M 《Annals of the rheumatic diseases》2012,71(6):1034-1041
1000.
Gossec L Smolen JS Gaujoux-Viala C Ash Z Marzo-Ortega H van der Heijde D FitzGerald O Aletaha D Balint P Boumpas D Braun J Breedveld FC Burmester G Cañete JD de Wit M Dagfinrud H de Vlam K Dougados M Helliwell P Kavanaugh A Kvien TK Landewé R Luger T Maccarone M McGonagle D McHugh N McInnes IB Ritchlin C Sieper J Tak PP Valesini G Vencovsky J Winthrop KL Zink A Emery P;European League Against Rheumatism 《Annals of the rheumatic diseases》2012,71(1):4-12